Abstract:Objective To investigate the mechanisms underlying the low dose cytarabine induced autophagy and differentiation in human acute myeloid leukemia (AML) cell lines in vitro. Introduction Cytarabine (Ara-C) is a fundamental drug used in the treatment of AML for years, but its specific mechanism of action is still not well documented. Autophagy, characterized by the formation of double-membrane vesicles called phagosomes, is a general process for degradation of cellular proteins and cytoplasmic organelles in many physiological and pathophysiological conditions. Recent studies have established the role of autophagy in cell differentiation and chemotherapy effects. Here we sought to determine the importance of autophagy in the AML treatment with especially low dose cytarabine (LD-Ara-C). Methods Cell viability after Ara-C treatment was evaluated using the Cell and Particle Counter. The expression of LC3, p62, Beclin 1 and Bcl-2 was detected by Western blot analysis, so as the Akt-mTOR pathway. Ultrastructural features in cells with or without Ara-C treatment were observed through transmission electron microscope (TEM).Cell morphology was determined by Wright-Giemsa staining. Flow cytometry was performed to examine cell differentiation and apoptosis in the presence or absence of 3-MA, a PI3K inhibitor, or CQ, a lysosomal inhibitor. A beclin1-specific short hairpin RNA (shRNA) was transfected into cells using lentivirus to obtain beclin1 silencing. Results The AML cell lines U937 and HEL were treated with increasing concentrations of Ara-C range from 10nM to 500nM for 24/48h and then analyzed for cell viability, which showed the growth inhibition rates in a time and dose-dependent manner. The cytotoxic effects of Ara-C on U937 cells were also studied by flow cytometry analysis of Annexin V/PI strained samples. Cell apoptosis and death were not detected when exposed to low concentration (10-50nM) while about 50% proliferation inhibition rate exists. To test whether autophagy was involved in the action of LD-Ara-C on leukemia cells, we detected microtubule-associated protein light chain 3 (LC3) conversion and sequestosome1 (p62) decrease by immunobloting. Treatment with LD-Ara-C (50nM) induced a time-dependent increase in the expression of LC3-Ⅱ and beclin1, but degradation of p62 in both U937 and HEL cells. Besides, vacuoles surrounded by a double membrane and containing cytoplasmic contents, a characteristic of autophagosomes appeared after 24h treatment, further suggesting an autophagic response caused by LD-Ara-C. Meanwhile, deregulation of Akt-mTOR pathway was also detected. LD-Ara-C induced increase of CD11b expression and morphologic changes of partial differentiation within 4 days in U937 revealed differentiation as another cellular effect of Ara-C in AML cells. When cultured in the presence of autophagy inhibitor, 3-MA or CQ, LD-Ara-C induced cell autophagy and differentiation were reversed, and cell growth inhibition was also attenuated. The similar phenomenon could also be seen when we down-regulated the expression of beclin1, an essential protein for the mammalian autophagy cascade, by shRNA transfection in U937 cells. Taken together, LD-Ara-C-induced autophagy appeared to play an important role in the following cell differentiation and death in AML cells. Conclusion Our data demonstrate that LD-Ara-C plays the therapeutic effect in human acute myeloid leukemia cells by triggering both autophagy and differentiation. Downreguation of Akt-mTOR pathway is involved in these processes. We suggest that cytarabine-induced autophagy is not a pro-survival mechanism, but accounts for its antineoplastic effects, which provides the first evidence for the potential of autophagy as a novel approach for AML treatment with LD-Ara-C, however the underlying mechanisms remain to be well elucidated. Disclosures No relevant conflicts of interest to declare.

Autophagy Contributes to Dasatinib-Induced Myeloid Differentiation of Human Acute Myeloid Leukemia Cells

CXCR4-mediated Signaling Regulates Autophagy and Influences Acute Myeloid Leukemia Cell Survival and Drug Resistance.

MEK/ERK Dependent Activation of STAT1 Mediates Dasatinib-Induced Differentiation of Acute Myeloid Leukemia

Data from Bortezomib Sensitizes Human Acute Myeloid Leukemia Cells to All-<i>Trans</i>-Retinoic Acid–Induced Differentiation by Modifying the RARα/STAT1 Axis

Autophagy Inhibition-induced Cytosolic DNA Sensing Combined with Differentiation Therapy Induces Irreversible Myeloid Differentiation in Leukemia Cells

Dasatinib synergizes with ATRA to trigger granulocytic differentiation in ATRA resistant acute promyelocytic leukemia cell lines via Lyn inhibition-mediated activation of RAF-1/MEK/ERK.

The HER2 Inhibitor TAK165 Sensitizes Human Acute Myeloid Leukemia Cells to Retinoic Acid-Induced Myeloid Differentiation by Activating MEK/ERK Mediated RARα/STAT1 Axis

ATP Depletion Triggers Acute Myeloid Leukemia Differentiation Through an ATR/Chk1 Protein-dependent and P53 Protein-independent Pathway

Dihydromyricetin sensitizes human acute myeloid leukemia cells to retinoic acid-induced myeloid differentiation by activating STAT1

Autophagy and Ubiquitin-Mediated Proteolytic Degradation of PML/Rarα Fusion Protein in Matrine-Induced Differentiation Sensitivity Recovery of ATRA-Resistant APL (NB4-LR1) Cells: in Vitro and in Vivo Studies

Autophagy Induction of Acute Myeloid Leukemia (aml) Cells after Treatment with Low Dose-Cytarabine (Ara-C) and Enhanced Cytocidal Effect on Aml Cells by Combined Treatment with Ara-C Plus Lenograstim.

Combined staurosporine and retinoic acid induces differentiation in retinoic acid resistant acute promyelocytic leukemia cell lines

A Genomic and Proteomic Research for the Regulatory Networks of Atra-Induced Differentiation of Acute Promyelocytic Leukemia Cells

CDK2 suppression synergizes with all-trans-retinoic acid to overcome the myeloid differentiation blockade of AML cells

Autophagy is an Important Event for Low Dose Cytarabine Treatment in Acute Myeloid Leukemia U937 Cell Line

Autophagy: New Insights into Mechanisms of Action and Resistance of Treatment in Acute Promyelocytic leukemia

The CDK4/6 inhibitor Palbociclib synergizes with ATRA to induce differentiation in AML

Trametinib Enhances ATRA-induced Differentiation in AML Cells.

Diptoindonesin G promotes ERK-mediated nuclear translocation of p-STAT1 (Ser727) and cell differentiation in AML cells

Combined Application of Salinomycin and ATRA Induces Apoptosis and Differentiation of Acute Myeloid Leukemia Cells by Inhibiting WNT/β-Catenin Pathway

Abstract A19: Targeting epigenetic regulators to override cellular identity programs and induce therapeutic differentiation in MLL-rearranged acute myeloid leukemia